Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 8/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | ABL2 | P42684 | 3/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655499 | 0.84 | MTOR (0.55) | ADKBTKMTORRAB9ASRC | |
| SCHEMBL29484542 | 0.83 | ADK (0.54) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL16236390 | 0.83 | ADK (0.54) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL18044604 | 0.80 | ADK (0.52) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL1939761 | 0.80 | ADK (0.52) | ADKSLC29A1BTKMTORRAB9A | |
| SCHEMBL401328 | 0.80 | ADK (0.52) | ADKSLC29A1MTORRAB9ASRC | |
| SCHEMBL16236685 | 0.79 | ADK (0.51) | ADKSLC29A1BTKMTORRAB9A | |
| SCHEMBL20351758 | 0.79 | ADK (0.54) | ADKSLC29A1MTORRAB9A | |
| SCHEMBL22086530 | 0.79 | ADK (0.51) | ADKSLC29A1BTKMTORRAB9A | |
| SCHEMBL30373169 | 0.79 | ADK (0.51) | ADKSLC29A1BTKMTORRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | ADK 983/4885SLC29A1 3030/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.